文献速递血管炎其他结缔组织病

儿童血管炎中腺苷脱氨酶2基因新变异及多样临床表型

Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis.
PubMed 文献 · Arthritis Rheumatol · 2019-08-26

研究对60例儿童期起病的系统性原发性血管炎患者进行ADA2编码外显子测序,鉴定出9例DADA2患者,其中8例携带双等位基因罕见变异(已知p.Gly47Arg/p.Gly47Ala或新变异p.Arg9Trp/p.Leu351Gln/p.Ala357Thr),临床表型广泛多样,提示对血管炎皮疹、不可分类血管炎、PAN或不明原因早发中枢神经系统病变伴系统性炎症的儿童筛查ADA2有助于早期诊断。

要点

  • 儿童PAN、 cutaneous PAN、不可分类血管炎或早发卒中患者应筛查ADA2基因。
  • DADA2基因型和表型异质性大,可见已知及新发双等位基因罕见变异。
  • DADA2患者可能对生物制剂治疗反应优于传统免疫抑制。

核心结论

  • DADA2具有广泛的基因型和表型变异性。
  • 对血管炎皮疹、不可分类血管炎、PAN或不明原因早发中枢神经系统病变伴系统性炎症的儿童筛查ADA2可能有助于早期诊断。

研究设计与样本

  • 对国际注册的60例儿童和青少年系统性原发性血管炎患者进行ADA2编码外显子测序。
  • 纳入诊断包括PAN、皮肤型PAN、不可分类血管炎、5岁及以下起病的任何慢性血管炎或有卒中史。
  • 通过ADA2酶活性和免疫印迹评估所鉴定变异的功能后果。

主要发现

  • 共鉴定出9例DADA2患者,其中5例PAN、3例不可分类血管炎、1例ANCA相关性血管炎。
  • 9例中1例无ADA2编码区罕见变异,8例携带双等位基因罕见变异(次要等位基因频率<0.01)。
  • 变异包括已知关联的p.Gly47Arg和p.Gly47Ala,以及新关联的p.Arg9Trp、p.Leu351Gln和p.Ala357Thr。
  • 临床表型差异广泛。

关键数值与推荐

  • 双等位基因罕见变异定义为次要等位基因频率<0.01。
  • 已知与DADA2关联的变异为p.Gly47Arg和p.Gly47Ala,新关联变异为p.Arg9Trp、p.Leu351Gln和p.Ala357Thr。

临床怎么用

  • 对儿童期起病的PAN、皮肤型PAN、不可分类血管炎、5岁及以下起病的慢性血管炎或有卒中史的患者,可考虑筛查ADA2基因。
  • 对血管炎皮疹、不可分类血管炎、PAN或不明原因早发中枢神经系统病变伴系统性炎症的儿童筛查ADA2,可能实现早期诊断。

局限性

  • 样本量较小(60例),可能限制结论的普遍性。
  • 研究为基因筛查注册队列,未报告治疗反应的前瞻性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Individuals with deficiency of adenosine deaminase 2 (DADA2), a recently recognized autosomal recessive disease, present with various systemic vascular and inflammatory manifestations, often with young age at disease onset or with early onset of recurrent strokes. Their clinical features and histologic findings overlap with those of childhood-onset polyarteritis nodosa (PAN), a primary "idiopathic" systemic vasculitis. Despite similar clinical presentation, individuals with DADA2 may respond better to biologic therapy than to traditional immunosuppression. The aim of this study was to screen an international registry of children with systemic primary vasculitis for variants in ADA2. METHODS: The coding exons of ADA2 were sequenced in 60 children and adolescents with a diagnosis of PAN, cutaneous PAN, or unclassifiable vasculitis (UCV), any chronic vasculitis with onset at age 5 years or younger, or history of stroke. The functional consequences of the identified variants were assessed by ADA2 enzyme assay and immunoblotting. RESULTS: Nine children with DADA2 (5 with PAN, 3 with UCV, and 1 with antineutrophil cytoplasmic antibody-associated vasculitis) were identified. Among them, 1 patient had no rare variants in the coding region of ADA2 and 8 had biallelic, rare variants (minor allele frequency <0.01) with a known association with DADA2 (p.Gly47Arg and p.Gly47Ala) or a novel association (p.Arg9Trp, p.Leu351Gln, and p.Ala357Thr). The clinical phenotype varied widely. CONCLUSION: These findings support previous observations indicating that DADA2 has extensive genotypic and phenotypic variability. Thus, screening ADA2 among children with vasculitic rash, UCV, PAN, or unexplained, early-onset central nervous system disease with systemic inflammation may enable an earlier diagnosis of DADA2.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gibson KM, Morishita KA, Dancey P, et al. Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis Rheumatol. 2019. PMID: 31008556. doi:10.1002/art.40913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。